A detailed history of Metis Global Partners, LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Metis Global Partners, LLC holds 62,513 shares of GILD stock, worth $5.3 Million. This represents 0.15% of its overall portfolio holdings.

Number of Shares
62,513
Previous 61,440 1.75%
Holding current value
$5.3 Million
Previous $4.5 Million 4.69%
% of portfolio
0.15%
Previous 0.17%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 06, 2024

BUY
$63.15 - $72.88 $67,759 - $78,200
1,073 Added 1.75%
62,513 $4.29 Million
Q1 2024

May 06, 2024

BUY
$71.58 - $87.29 $126,696 - $154,503
1,770 Added 2.97%
61,440 $4.5 Million
Q4 2023

Feb 06, 2024

SELL
$73.27 - $83.09 $139,506 - $158,203
-1,904 Reduced 3.09%
59,670 $4.83 Million
Q3 2023

Nov 07, 2023

BUY
$73.94 - $80.67 $927,577 - $1.01 Million
12,545 Added 25.59%
61,574 $4.61 Million
Q2 2023

Aug 07, 2023

SELL
$76.01 - $86.7 $174,746 - $199,323
-2,299 Reduced 4.48%
49,029 $3.78 Million
Q1 2023

May 08, 2023

BUY
$77.31 - $88.08 $544,494 - $620,347
7,043 Added 15.9%
51,328 $4.26 Million
Q4 2022

Feb 07, 2023

BUY
$62.32 - $89.47 $1 Million - $1.44 Million
16,123 Added 57.25%
44,285 $3.8 Million
Q3 2022

Nov 08, 2022

SELL
$59.54 - $68.01 $48,108 - $54,952
-808 Reduced 2.79%
28,162 $1.74 Million
Q2 2022

Aug 08, 2022

BUY
$57.72 - $65.01 $385,858 - $434,591
6,685 Added 30.0%
28,970 $1.79 Million
Q1 2022

May 03, 2022

BUY
$57.92 - $72.58 $514,792 - $645,091
8,888 Added 66.34%
22,285 $1.33 Million
Q4 2021

Feb 11, 2022

BUY
$64.88 - $73.64 $869,197 - $986,555
13,397 New
13,397 $973,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $106B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Metis Global Partners, LLC Portfolio

Follow Metis Global Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Metis Global Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Metis Global Partners, LLC with notifications on news.